MCID: OPT003
MIFTS: 54

Opiate Dependence

Categories: Mental diseases

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Name: Opiate Dependence 12 15
Opioid-Related Disorders 44 73
Opioid Dependence 76 55
Opioid Type Dependence 12
Opiate Addiction 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2559
ICD10 33 F11.2
ICD9CM 35 304.0 304.00
MeSH 44 D009293

Summaries for Opiate Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid-related disorders, is related to opioid dependence 1 and morphine dependence. An important gene associated with Opiate Dependence is ODS1 (Opioid Dependence, Susceptibility To, 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Buprenorphine and Heroin have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and skin, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Opioid use disorder is a medical condition characterized by a problematic pattern of opioid use that... more...

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 opioid dependence 1 34.0 ODS1 OPRM1
2 morphine dependence 30.5 OPRD1 OPRK1 OPRM1
3 opioid addiction 29.7 DRD2 OPRD1 OPRK1 OPRM1
4 personality disorder 29.5 DRD2 DRD3 SLC6A4 TPH1
5 heroin dependence 29.4 DRD2 OPRD1 OPRM1 PDYN
6 schizophrenia 28.2 DRD2 DRD3 SLC6A4 TH TPH1
7 disease of mental health 27.6 DRD2 DRD3 OPRM1 PDYN POMC SLC6A4
8 alcohol dependence 25.1 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
9 obsessive-compulsive personality disorder 10.8 DRD3 SLC6A4
10 acidophil adenoma 10.6 IGF1 POMC
11 pituitary infarct 10.6 IGF1 POMC
12 sick building syndrome 10.6 POMC VEGFA
13 empty sella syndrome 10.5 IGF1 POMC
14 sheehan syndrome 10.5 IGF1 POMC
15 toxic encephalopathy 10.4 CREB1 NGF TH
16 cerebral hypoxia 10.4 CREB1 IGF1
17 mental depression 10.4 POMC SLC6A4 TPH1
18 hyperpituitarism 10.4 IGF1 POMC
19 chronic fatigue syndrome 10.3 IGF1 POMC SLC6A4
20 alcohol-induced mental disorder 10.3 DRD2 SLC6A4
21 panic disorder 10.3 POMC SLC6A4 TPH1
22 west syndrome 10.3 POMC TH TPH1
23 anorexia nervosa 10.3 IGF1 POMC SLC6A4
24 pituitary tumors 10.3 IGF1 POMC VEGFA
25 polysubstance abuse 10.3 DRD2 DRD3
26 nervous system disease 10.3 NGF TH VEGFA
27 retrograde amnesia 10.3 PDYN POMC SLC6A4
28 tardive dyskinesia 10.2 DRD2 DRD3
29 phobic disorder 10.2 OPRK1 SLC6A4
30 prolactin producing pituitary tumor 10.2 DRD2 NGF
31 impulse control disorder 10.2 DRD2 DRD3
32 galactorrhea 10.2 DRD2 IGF1
33 alcoholic psychosis 10.2 DRD2 SLC6A4
34 pathological gambling 10.2 DRD2 DRD3 SLC6A4
35 migraine without aura 10.2 DRD2 DRD3 SLC6A4
36 somatoform disorder 10.1 NGF OPRM1 TPH1
37 delusional disorder 10.1 DRD2 DRD3 TH
38 pheochromocytoma 10.1 CREB1 NGF POMC TH
39 aging 10.1
40 substance abuse 10.1 DRD2 DRD3 SLC6A4
41 alcohol abuse 10.1 DRD2 DRD3 SLC6A4
42 schizoaffective disorder 10.1 DRD2 DRD3 SLC6A4
43 depression 10.1
44 cutaneous solitary mastocytoma 10.1 PDYN POMC
45 social phobia 10.1 DRD2 SLC6A4
46 eating disorder 10.1 DRD2 POMC SLC6A4
47 movement disease 10.0 DRD2 DRD3 TH
48 hypothyroidism, congenital, nongoitrous, 4 10.0 IGF1 POMC
49 generalized anxiety disorder 10.0 DRD2 SLC6A4 TPH1
50 conduct disorder 10.0 DRD2 SLC6A4 TPH1

Graphical network of the top 20 diseases related to Opiate Dependence:



Diseases related to Opiate Dependence

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 DRD2 NGF DRD3 OPRD1 CREB1 OPRM1
2 homeostasis/metabolism MP:0005376 10.28 IGF1 DRD2 NGF DRD3 CREB1 OPRK1
3 growth/size/body region MP:0005378 10.23 IGF1 DRD2 NGF DRD3 CREB1 OPRM1
4 cardiovascular system MP:0005385 10.21 CREB1 IGF1 DRD2 NGF DRD3 POMC
5 integument MP:0010771 10.18 IGF1 DRD2 NGF OPRD1 OPRM1 SLC6A4
6 endocrine/exocrine gland MP:0005379 10.13 CREB1 IGF1 DRD2 OPRK1 POMC SLC6A4
7 adipose tissue MP:0005375 10.08 IGF1 DRD2 DRD3 POMC OPRM1 PDYN
8 mortality/aging MP:0010768 10.07 CREB1 IGF1 DRD2 NGF DRD3 POMC
9 nervous system MP:0003631 10.07 IGF1 DRD2 NGF DRD3 OPRD1 CREB1
10 digestive/alimentary MP:0005381 9.97 DRD2 DRD3 OPRK1 OPRM1 PDYN VEGFA
11 muscle MP:0005369 9.87 CREB1 IGF1 DRD2 NGF SLC6A4 TPH1
12 no phenotypic analysis MP:0003012 9.76 DRD2 NGF OPRM1 TH PDYN OPRD1
13 normal MP:0002873 9.56 CREB1 IGF1 DRD2 NGF SLC6A4 OPRM1
14 respiratory system MP:0005388 9.1 CREB1 IGF1 DRD2 TPH1 VEGFA TH

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 323)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 52485-79-7 40400 644073
2
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 561-27-3 5462328
3
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
4
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 76-99-3 4095
5
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 465-65-6 5284596
6
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 16590-41-3 5360515
7
Nicotine Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 54-11-5 942 89594
8
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
9
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 437-38-7 3345
11
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-36-2 5760 446220
12
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
13
Ribavirin Approved Phase 4,Phase 3,Not Applicable 36791-04-5 37542
14
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
15
Valproic Acid Approved, Investigational Phase 4,Not Applicable 99-66-1 3121
16
Norepinephrine Approved Phase 4,Phase 1,Phase 2 51-41-2 439260
17
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 113775-47-6 68602 5311068
18
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 137-58-6 3676
19
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-42-6 5284603
20
Buspirone Approved, Investigational Phase 4 36505-84-7 2477
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
22
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 57-27-2 5288826
23
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60142-96-3 3446
24
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2,Not Applicable 56-12-2 119
25
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
26
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
27
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
28
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 3 2180-92-9, 38396-39-3 2474
29
Acetazolamide Approved, Vet_approved Phase 4,Phase 2 59-66-5 1986
30
Remifentanil Approved Phase 4,Phase 3 132875-61-7 60815
31
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
32
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
33 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Narcotics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Opiate Alkaloids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antitussive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Anesthetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Anesthetics, General Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Anesthetics, Intravenous Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 598)
# Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
3 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4 Buprenorphine patch and sublingual tablets
4 Determine the Safety of a Sublingual Tablet Formulation of Buprenorphine and Naloxone by Extending the Combination Tablet Availability to Physicians in Office-Based Practice Completed NCT00007527 Phase 4 naloxone;buprenorphine
5 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
6 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
7 Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
8 Multicentre Trial of Suboxone in Opiate-dependent Subjects in Taiwan Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
9 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
10 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4 Buprenorphine/naloxone
11 Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
12 A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
13 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
14 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
15 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
16 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
17 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
18 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
19 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
20 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
21 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
22 Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED) Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
23 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
24 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
25 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
26 Desvenlafaxine in Opioid-Dependent Patients Completed NCT02200406 Phase 4 Desvenlafaxine
27 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment Completed NCT02032433 Phase 4 Extended-Release Naltrexone;Buprenorphine-Naloxone
28 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
29 Naltrexone Treatment for Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
30 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
31 Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT Completed NCT01471145 Phase 4 Naltrexone
32 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
33 Feasibility Study of Take-Home LAAM Medication - 3 Completed NCT00000300 Phase 4 LAAM
34 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
35 A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery Completed NCT01374763 Phase 4 Oxycodone;Prolonged-release oxycodone/naloxone
36 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
37 Attention Training for Opioid-maintained Cocaine Users Completed NCT01870882 Phase 4
38 Effects of Buspirone in Opiate Withdrawal Completed NCT00326235 Phase 4 Buspirone
39 A Stepwise Strategy Utilizing Buprenorphine and Methadone Completed NCT00310934 Phase 4 methadone;buprenorphine / methadone sequence
40 A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic Recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir
41 Houston Emergency Opioid Engagement System Recruiting NCT03396276 Phase 4 Suboxone
42 Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO) Recruiting NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
43 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Naltrexone;Methadone;Isoniazid;Rifapentine
44 Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures Recruiting NCT03305666 Phase 4 Liposomal bupivacaine injection;Bupivacaine indwelling catheter
45 Switch to Genvoya Followed by HCV Therapy With Epclusa in Patients With HIV/HCV Co-Infection on Methadone Recruiting NCT03549312 Phase 4 Genvoya;Epclusa
46 Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry Recruiting NCT01999946 Phase 4 Extended-Release Naltrexone
47 Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia Recruiting NCT02992938 Phase 4 Acetazolamide;Placebo Oral Tablet
48 Biomarkers of Injectable Extended Release Naltrexone Treatment Active, not recruiting NCT02324725 Phase 4 Naltrexone
49 Extended Release Naltrexone for Opioid-Dependent Youth Active, not recruiting NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
50 Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain Active, not recruiting NCT02741076 Phase 4 Morphine Sulfate ER;Oxycodone ER;Oxymorphone ER

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: opioid-related disorders

Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

41
Testes, Brain, Skin, Liver, Bone, Prefrontal Cortex, Cortex

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 249)
# Title Authors Year
1
Opiate Dependence or Addiction?: A Review of the Centers for Disease Control and Prevention Guidelines for Management of Chronic Pain. ( 29505462 )
2018
2
Predicting health-related quality of life (EQ-5D-5A L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP. ( 29843726 )
2018
3
Breastfeeding support and opiate dependence: A think aloud study. ( 28494389 )
2017
4
Opiate dependence induces cell type-specific plasticity of intrinsic membrane properties in the rat juxtacapsular bed nucleus of stria terminalis (jcBNST). ( 28986608 )
2017
5
Regional cerebral blood flow in opiate dependence relates to substance use and neuropsychological performance. ( 28627790 )
2017
6
Nonopiate Methods for Treatment of Opiate Dependence. ( 29368475 )
2016
7
Frontal Metabolite Concentration Deficits in Opiate Dependence Relate to Substance Use, Cognition, and Self-Regulation. ( 27695638 )
2016
8
Buprenorphine Maintenance Treatment of Opiate Dependence: Correlations Between Prescriber Beliefs and Practices. ( 26771870 )
2016
9
A thalamic input to the nucleus accumbens mediates opiate dependence. ( 26840481 )
2016
10
An economic evaluation of contingency management for completion of hepatitis B vaccination in those on treatment for opiate dependence. ( 26990598 )
2016
11
TPH1 and 5-HTTLPR Genes Specifically Interact in Opiate Dependence but Not in Alcohol Dependence. ( 27045756 )
2016
12
Measuring Health and Broader Well-Being Benefits in the Context of Opiate Dependence: The Psychometric Performance of the ICECAP-A and the EQ-5D-5L. ( 27712710 )
2016
13
Influence of Psychiatric and Personality Disorders on Smoking Cessation Among Individuals in Opiate Dependence Treatment. ( 27064523 )
2016
14
A prospective, longitudinal study of sleep disturbance and comorbidity in opiate dependence (the ANRS Methaville study). ( 26753792 )
2016
15
Retention in Medication-Assisted Treatment for Opiate Dependence: A Systematic Review. ( 26467975 )
2015
16
Role of Temperament, Personality Traits and Onset Age of Smoking in Predicting Opiate Dependence. ( 26870712 )
2015
17
Analysis of connectivity in NeuCube spiking neural network models trained on EEG data for the understanding of functional changes in the brain: A case study on opiate dependence treatment. ( 26000776 )
2015
18
Evidence of anhedonia and differential reward processing in prefrontal cortex among post-withdrawal patients with prescription opiate dependence. ( 26711857 )
2015
19
Interim Buprenorphine Treatment in Opiate Dependence: A Pilot Effectiveness Study. ( 26176490 )
2015
20
Opiate dependence in schizophrenia: case presentation and literature review. ( 25392062 )
2014
21
Buprenorphine for opiate dependence: clinic based therapy in Israel. ( 25841225 )
2014
22
Opiate dependence induces network state shifts in the limbic system. ( 23911767 )
2013
23
Medication-assisted treatment of opiate dependence is gaining favor. ( 23733899 )
2013
24
Association between DRD2, 5-HTTLPR, and ALDH2 genes and specific personality traits in alcohol- and opiate-dependent patients. ( 23685324 )
2013
25
Social stress engages opioid regulation of locus coeruleus norepinephrine neurons and induces a state of cellular and physical opiate dependence. ( 23660707 )
2013
26
Opiate dependence as an independent and interactive risk factor for arterial stiffness and cardiovascular ageing - a longitudinal study in females. ( 23976908 )
2013
27
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. ( 23624062 )
2013
28
Effects of opiate dependence through different administration routes on pulmonary inflammation and its severity. ( 24693370 )
2013
29
Manifold implications of forgotten hyperglycemia in clinical opiate dependence. ( 22313373 )
2013
30
Medically assisted recovery from opiate dependence within the context of the UK drug strategy: methadone and Suboxone (buprenorphine-naloxone) patients compared. ( 22703715 )
2013
31
Enlarged cavum septum pellucidum as a neurodevelopmental marker in adolescent-onset opiate dependence. ( 24205275 )
2013
32
Take home maintenance medication in opiate dependence. ( 23837085 )
2013
33
Duration of opiate exposure as a determinant of arterial stiffness and vascular age in male opiate dependence: a longitudinal study. ( 24329809 )
2013
34
Receipt of prescribed controlled substances by adolescents and young adults prior to presenting for opiate dependence treatment. ( 24826367 )
2013
35
Elevated IGF1 in clinical opiate dependence. ( 23524620 )
2013
36
Exercise as an adjuvant intervention in opiate dependence. ( 23577897 )
2013
37
Relative and age-dependent stimulation of soluble and cellular immunity in opiate dependence. ( 21918466 )
2012
38
Differing age related trajectories of dysfunction in several organ systems in opiate dependence. ( 21339699 )
2012
39
Effect of craving induction on inhibitory control in opiate dependence. ( 21952672 )
2012
40
Premature ejaculation and other sexual dysfunctions in opiate dependent men receiving methadone substitution treatment. ( 21920671 )
2012
41
KPNA3 variation is associated with schizophrenia, major depression, opiate dependence and alcohol dependence. ( 22960338 )
2012
42
Alpha-synuclein and heroin craving in opiate-dependent patients on injectable heroin maintenance. ( 21309955 )
2012
43
Ecological momentary assessment in alcohol, tobacco, cannabis and opiate dependence: a comparison of feasibility and validity. ( 22647899 )
2012
44
Association of nerve growth factor and vascular endothelial growth factor A with psychometric measurements of opiate dependence: results of a pilot study in patients participating in a structured diamorphine maintenance program. ( 22517242 )
2012
45
The effect of pain on stroop performance in patients with opiate dependence in sustained remission. ( 21769047 )
2011
46
Deterioration of indices of aortic augmentation and vascular age predate major cardiac events and interact with opiate dependence. ( 19327850 )
2011
47
Functional imaging of emotion reactivity in opiate-dependent borderline personality disorder. ( 22448769 )
2011
48
Pharmacological treatments of opiate dependence. ( 21524267 )
2011
49
Serum levels of BDNF are associated with craving in opiate-dependent patients. ( 21890593 )
2011
50
Association between Novelty Seeking of opiate-dependent patients and the catechol-O-methyltransferase Val(158)Met polymorphism. ( 20728009 )
2010

Variations for Opiate Dependence

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 CREB1 DRD2 DRD3 IGF1 NGF OPRD1
2
Show member pathways
13.31 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
3
Show member pathways
12.86 CREB1 NGF OPRM1 PDYN POMC
4
Show member pathways
12.75 CREB1 DRD2 DRD3 OPRM1 TH VEGFA
5
Show member pathways
12.28 CREB1 OPRM1 PDYN POMC
6 12.17 CREB1 NGF OPRM1 POMC TH TPH1
8
Show member pathways
11.74 CREB1 DRD2 PDYN TH
9 11.68 OPRD1 OPRM1 POMC VEGFA
10
Show member pathways
11.64 DRD2 DRD3 TH
11 11.46 IGF1 NGF TH VEGFA
12 11.31 CREB1 NGF SLC6A4 TH TPH1 VEGFA
13
Show member pathways
10.88 TH TPH1
14 10.87 DRD2 DRD3
15 10.81 CREB1 TH

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.72 CREB1 DRD2 NGF OPRM1 TH
2 dendrite GO:0030425 9.63 DRD2 NGF OPRK1 OPRM1 PDYN TH
3 perikaryon GO:0043204 9.56 DRD2 OPRK1 OPRM1 TH
4 neuron projection GO:0043005 9.43 OPRD1 OPRK1 OPRM1 SLC6A4 TH TPH1
5 axon terminus GO:0043679 8.92 DRD2 OPRD1 OPRK1 PDYN

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.99 OPRD1 OPRM1 POMC VEGFA
2 chemical synaptic transmission GO:0007268 9.97 OPRD1 OPRK1 OPRM1 PDYN
3 response to drug GO:0042493 9.97 CREB1 DRD2 DRD3 SLC6A4 TH
4 response to organic substance GO:0010033 9.86 CREB1 IGF1 SLC6A4
5 circadian rhythm GO:0007623 9.85 CREB1 SLC6A4 TPH1
6 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.83 OPRD1 OPRK1 OPRM1
7 response to hypoxia GO:0001666 9.83 CREB1 DRD2 SLC6A4 TH VEGFA
8 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.82 OPRD1 OPRK1 OPRM1
9 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.82 OPRD1 OPRK1 OPRM1
10 cellular response to growth factor stimulus GO:0071363 9.81 CREB1 OPRD1 TH
11 sensory perception of pain GO:0019233 9.81 OPRD1 OPRK1 OPRM1
12 social behavior GO:0035176 9.79 DRD3 SLC6A4 TH
13 visual learning GO:0008542 9.79 CREB1 DRD2 DRD3
14 memory GO:0007613 9.78 CREB1 NGF SLC6A4 TH
15 response to nicotine GO:0035094 9.77 CREB1 DRD2 TH
16 positive regulation of receptor internalization GO:0002092 9.73 DRD2 VEGFA
17 response to immobilization stress GO:0035902 9.73 TH TPH1
18 regulation of sensory perception of pain GO:0051930 9.73 OPRD1 OPRK1 OPRM1
19 regulation of dopamine secretion GO:0014059 9.72 DRD2 DRD3
20 dopamine receptor signaling pathway GO:0007212 9.72 DRD2 DRD3
21 positive regulation of neuroblast proliferation GO:0002052 9.72 DRD2 VEGFA
22 positive regulation of Ras protein signal transduction GO:0046579 9.72 IGF1 NGF
23 response to ethanol GO:0045471 9.72 DRD2 DRD3 OPRK1 OPRM1 TH
24 eye photoreceptor cell development GO:0042462 9.71 TH VEGFA
25 positive regulation of long-term synaptic potentiation GO:1900273 9.71 CREB1 DRD2
26 negative regulation of protein secretion GO:0050709 9.71 DRD2 DRD3
27 mammary gland alveolus development GO:0060749 9.71 TPH1 VEGFA
28 response to growth factor GO:0070848 9.71 OPRM1 TH
29 estrous cycle GO:0044849 9.7 OPRK1 OPRM1
30 positive regulation of CREB transcription factor activity GO:0032793 9.7 OPRD1 VEGFA
31 behavioral response to ethanol GO:0048149 9.7 DRD2 OPRM1
32 dopamine metabolic process GO:0042417 9.7 DRD2 DRD3
33 response to amphetamine GO:0001975 9.7 DRD2 DRD3 TH
34 positive regulation of renal sodium excretion GO:0035815 9.69 DRD2 DRD3
35 neurotransmitter biosynthetic process GO:0042136 9.69 SLC6A4 TH
36 behavioral response to cocaine GO:0048148 9.69 DRD2 DRD3 OPRK1
37 prepulse inhibition GO:0060134 9.68 DRD2 DRD3
38 G-protein coupled receptor internalization GO:0002031 9.68 DRD2 DRD3
39 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.67 DRD2 DRD3
40 synaptic transmission, dopaminergic GO:0001963 9.67 DRD2 DRD3 TH
41 response to cocaine GO:0042220 9.67 DRD2 DRD3 OPRK1 OPRM1
42 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.66 DRD3 OPRM1
43 aromatic amino acid family metabolic process GO:0009072 9.66 TH TPH1
44 neuropeptide signaling pathway GO:0007218 9.65 OPRD1 OPRK1 OPRM1 PDYN POMC
45 sensory perception GO:0007600 9.63 OPRK1 OPRM1 PDYN
46 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.62 DRD2 DRD3
47 acid secretion GO:0046717 9.59 DRD2 DRD3
48 negative regulation of dopamine receptor signaling pathway GO:0060160 9.58 DRD2 DRD3
49 response to histamine GO:0034776 9.58 DRD2 DRD3
50 opioid receptor signaling pathway GO:0038003 9.58 OPRD1 OPRK1 OPRM1

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G-protein coupled receptor activity GO:0004930 9.85 DRD2 DRD3 OPRD1 OPRK1 OPRM1
2 obsolete signal transducer activity GO:0004871 9.73 DRD2 DRD3 OPRD1 OPRM1
3 peptide binding GO:0042277 9.54 OPRD1 OPRK1 OPRM1
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.4 DRD2 DRD3
5 neuropeptide binding GO:0042923 9.33 OPRD1 OPRK1 OPRM1
6 dopamine neurotransmitter receptor activity GO:0004952 9.32 DRD2 DRD3
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.26 TH TPH1
8 dopamine binding GO:0035240 9.13 DRD2 DRD3 TH
9 opioid receptor activity GO:0004985 8.8 OPRD1 OPRK1 OPRM1

Sources for Opiate Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....